N Govindarajan, Managing Director of Aurobindo Pharma, at the company#39;s earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.Aurobindo Pharma, Vaxxinity seek DCGI nod to begin Phase-2/3 of COVID-19 jab UB-612
N Govindarajan, Managing Director of Aurobindo Pharma, at the company#39;s earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment